24/7 Market News Snapshot 09 June, 2025 – Anixa Biosciences, Inc. (NASDAQ:ANIX)

June 9, 2025

DENVER, Colo., 09 June, 2025 (www.247marketnews.com) – (NASDAQ:ANIX) are discussed in this article.
Anixa Biosciences, Inc. (ANIX) has recently experienced significant market activity, with its stock surging by over 22%, jumping from a previous close of $2.760 to an impressive $3.369. The trading volume reached approximately 660.14K, indicating strong investor engagement and interest in Anixa’s promising biotechnology innovations aimed at advancing cancer treatment and prevention.

The surge in stock price coincides with Anixa’s announcement regarding its upcoming presentation at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025. Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at a prominent cancer institution and a principal investigator for Anixa’s Phase 1 clinical trial on ovarian cancer CAR-T immunotherapy, will present groundbreaking results from this clinical trial. Scheduled for June 19-21, 2025, the e-poster presentation, titled “Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer,” aims to unveil innovative findings that could significantly impact treatment strategies for recurrent ovarian cancer.

Anixa’s commitment to revolutionizing cancer care is further demonstrated through collaborations with leading research institutions, including a distinguished cancer center, and its development of various cancer vaccines, including those targeting breast and ovarian cancers in partnership with the Cleveland Clinic. As Anixa prepares to present its enlightening research at such a prestigious scientific conference, the company emphasizes its dedication to using advanced CAR-T technology to enhance treatment efficacy and improve patient outcomes.

With a strong focus on advancing therapies that leverage the body’s own immune system to combat cancer, Anixa continues to drive innovations that promise to transform the landscape of oncology for patients worldwide. Observers in the market and healthcare sectors are keenly anticipating updates from ESMO and further developments in Anixa’s research initiatives.

Related news for (ANIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.